Navigation Links
Medicago reports positive Phase I results for its avian flu pandemic vaccine
Date:12/21/2009

e groups and the placebo. As planned in the initial design, adverse event monitoring will continue for six months after administration of the second vaccine dose. The trial was conducted at the Vaccine Evaluation Center of McGill University in Montreal, Canada, under the supervision of Dr. Brian Ward.

Preliminary results showed that 81% of immunized subjects developed an immune response against the H5N1 virus after the second immunization. A four-fold increase in HI titers from baseline in 58% of subjects was observed in the 20 mcg group. HI titers greater than 1:40 were developed in 50% of the subjects in the 20 mcg group. The H5N1 vaccine also induced the production of antibodies cross-reacting with two other strains of H5N1 Avian Influenza suggesting Medicago's vaccine potential for cross-protection.

"Results at these lower dosage levels have not been reported for an H5N1 vaccine manufactured with a novel vaccine manufacturing technology," said Nathalie Landry, VP Product Development of Medicago. "H5N1 vaccines are poorly immunogenic in humans and are known to require repeated administrations with an adjuvant to elicit an immune response at low doses."

Full results of this trial will be submitted for publication in a scientific journal and will be available in the coming months. Based on these results, Medicago will proceed with a Phase II clinical trial, expected to commence during the first half of 2010.

About Medicago's pandemic flu vaccine candidate

Medicago's H5N1 vaccine candidate was formulated to protect against the Indonesian influenza virus. It is manufactured in Nicotiana benthamiana, a relative of the tobacco plant, using the Company's proprietary VLP technology. VLPs may have several advantages over traditional flu vaccines. They are made to look like a virus, allowing them to be recognized readily by the body's immune system, however, they lack the core genetic material making them
'/>"/>

SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Medicago succesfully expresses VLP antigen for A H1N1 strain
3. Medicagos H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
4. Medicago receives regulatory approval to begin human clinical testing with its avian flu pandemic vaccine
5. Medicago begins human clinical testing with its avian flu pandemic vaccine
6. Medicago awarded contract by the U.S. Army to explore applications of its plant-based technology in renewable energy
7. Medicago to present at the U.S. Department of Health and Human Services Global Health Security Initiative Workshop
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Bina Technologies, Inc. (Bina, Redwood ... have been acquired by Roche (SIX: RO, ROG; OTCQX: ... company that provides a big data platform for centralized ... for the academic and translational research markets.  Bina will ... continue to focus on development of their innovative genomic ...
(Date:12/19/2014)... Fayetteville, Arkansas (PRWEB) December 18, 2014 ... plans to locate its pilot production facility and ... further develop and produce innovative new materials that ... was chosen not only because of its historic, ... regional leaders’ efforts to attract leading edge, technology-based ...
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 iLab ... announced the appointment of Siri Bryant as the new ... new Director of Core Implementations. These two new leadership ... outstanding customer service by ensuring that iLab continues to ... “In the last four years, iLab has been deployed ...
(Date:12/19/2014)... , Dec. 18, 2014  Decision Resources Group finds ... biomaterial market will grow moderately through 2023 as the ... growing awareness of dental biomaterials all spur procedure volumes. ... as China and ... dental procedures within reach for a larger proportion of ...
Breaking Biology Technology:Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 2Asia Pacific Dental Biomaterial Market Will Grow Strongly Through 2023 3
... May 13 A guide to BRCA1 and ... resource is designed to equip physicians and other healthcare professionals who are ... the complexities of BRCA1/2 gene testing. , ... According to the American Cancer Society, ...
... TIANJIN, China , May 13 /PRNewswire-Asia/ -- A ... of,Biotechnology and Medicine (TJAB) and Genzyme Corporation was held in the,Tianjin ... , , ... executives including Rao Zihe, President of TJAB and,President of Nankai University, ...
... May 13  Fibrocell Science, Inc. (OTC Bulletin ... of autologous cell therapies for aesthetic, medical and scientific ... study (IT-H-001) of azficel-T, an autologous cell therapy currently ... (FDA) for the treatment of moderate to severe nasolabial ...
Cached Biology Technology:Hayes, Inc. Releases Guide to BRCA1 and BRCA2 Genetic Testing 2Tianjin International Joint Academy of Biotechnology and Medicine, Genzyme Enter into Strategic Partnership 2Fibrocell Science, Inc. Initiates Histology Study of azficel-T 2Fibrocell Science, Inc. Initiates Histology Study of azficel-T 3
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 16, 2014 ... has licensed its PerformTek biometric technology to industry leaders ... their highly accurate, clinically validated, biometric wearable products. These ... January 6-9 in Las Vegas . ... the technology is accurate, flexible and robust – with ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced ... the APAC Region 2015-2019"  report to their offering. ... this market is advances in technology. With continuous ... biometric solutions to the latest standard that meets ...
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... Geology articles this month are open access: "Steady ... during fault slip: Evidence from the rock record." Other ... whale "intestinal products" in central Italy to flooding as ... new findings via the Compact Reconnaissance Imaging Spectrometer for ...
... fatal case of potato poisoning: James B. Matheney of Vandalia, ... tubers, which had turned green due to sunlight exposure. Two ... wife, two daughters and four sons -- showed symptoms of ... the potatoes, and a breast-fed baby boy. His wife, aged ...
... years ago, two former Stanford University postdoctoral fellows, one ... the Harvard Stem Cell Institute (HSCI) in Cambridge, began ... healthy blood cells. What was it, they asked, that ... And after almost a decade of bicoastal collaboration, ...
Cached Biology News:Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 2Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 3Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 4Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 5Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 6Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 7Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 8Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 9Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 10Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 11Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 12Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 13Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 14Ancient whale coprolites, fault slickensides, shergottites, Ediacara, and Cascadia 15The pathway to potato poisons 2Cross-country collaboration leads to new leukemia model 2Cross-country collaboration leads to new leukemia model 3
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Component of HyperMu™ Insertion Kit...
Recombinant Rhesus Macaque IFN-alpha...
chk 1 kinase...
Biology Products: